从传统的经典药物如二甲双胍、磺酰脲类,到近年来的二肽基肽酶-4(DPP-4)抑制剂、SGLT-2 抑制剂及胰高糖素样肽-1(GLP-1)受体激动剂等产品的问世,患者对新型降糖药有了更多选择,这些药物不仅在降糖机制上各有千秋,在改善患者胰岛功能、减轻体重、降低心血管及肾脏疾病风险等方面也展现出各自显著优势。与此同时...
内容提示: Society Guidelines2022 Canadian Cardiovascular Society Guideline for Use ofGLP-1 Receptor Agonists and SGLT2 Inhibitors forCardiorenal Risk Reduction in AdultsPrimary Panel: G.B. John Mancini, MD (Co-chair), a Eileen O’Meara, MD (Co-chair), bShelley Zieroth, MD, c Mathieu ...
Screenshots iPad iPhone Description This tool can be used for peer-to-peer, physician-to-patient, and physician-to-caregiver discussions, allowing you to virtually explore two important drug classes used in type 2 diabetes: SGLT2 inhibitors and GLP-1 receptor agonists. The benefits of these agent...
the cellular mechanisms associated with CV protection afforded by these agents, investigating a pleiotropic range of potential effects to improve bone marrow (BM), kidney, heart, and vascular health. Additionally, there is gr...
Nonalcoholic fatty liver disease (NAFLD) is a growing epi-demic, representing the most common chronic liver disease worldwide.1 NAFLD is highly associated with type 2 diabe-tes mellitus (T2DM) and obesity, conditions that increase morbidity and mortality.2 A background of T2DM has also been ...
(SGLT-2is)andglucagon-likepeptide-1receptoragonists(GLP-1RAs)bothprovideeffectiveglycemiccontrolandhavebeenshowntoreducecardiovascular(CV)eventsinpatientswithT2DandahighCVriskorestablishedCVdisease.Becausetheseagentshavecomplementarymechanismsofaction,theyareabletoactonmultipledefectsofT2Dwhenusedincombination.Thisreview...
III. GLP-1 RA (with or without other GLD but not SGLT2i). IV. SGLT2i and GLP-1 RA (use of both with and without other GLD). V. Other GLD (without SGLT2i or GLP-1 RA). VI. No GLD (but diabetes diagnosis). Outcome Major adverse cardiovascular event (MACE): first of all-ca...
综上所述,与接受DPP-4i治疗的患者相比,接受SGLT-2i治疗的患者(尤其是艾托格列净和恩格列净)的新发青光眼风险显著较低,与GLP-1RA作为活性对照的敏感性分析中,这一关联的稳健程度较低但依旧显著。并且,SGLT-2i对开角型青光眼和闭角...
在本次大会上,南京大学医学院附属鼓楼医院朱大龙教授分享了《中国糖尿病防治指南》2024版的更新内容。新版指南中提到,伴ASCVD或其高危状态的T2DM患者,首选有ASCVD获益证据的胰高糖素样肽-1受体激动剂(GLP-1RA)或SGLT2i。T2DM患者合并HF者降糖药首选SGLT2i;伴CKD的T2DM患者,首选有CKD获益证据的SGLT2i。
This study aimed to observe the effect of the novel combination of dual add-on therapy of a sodium-glucose co-transporter-2 (SGLT2) inhibitor to a glucagon-like peptide-1 receptor agonist (GLP-1 RA) on glycaemic control and weight in patients with suboptimal diabetes control who are already...